ISTH 2023 | Unmet needs in hemophilia B: treating patients who develop inhibitors
Katharina Holstein, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, comments on unmet needs in hemophilia B, drawing focus on the challenges of treating patients who develop factor IX (FIX) inhibitors. Dr Holstein discusses the problems that can arise with immune tolerance induction (ITI) in these patients, and shares some recommended approaches and novel therapies which may improve patient outcomes. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Grants for research or clinical studies (to institution): Bayer, CSL Behring, NovoNordisk, Pfizer, Sobi
Honoraria for lectures or consultancy (to person):
Bayer, Biotest, Chugai, CSL Behring, LFB, Novo Nordisk, Pfizer, Roche, Sobi, Takeda
